Equine Gastric Ulcer Syndrome: An Update on Current Knowledge
Jessica Vokes1, Amy Lovett1, Benjamin Sykes1
1Equine Veterinary Clinic, School of Veterinary Sciences, Massey University, Palmerston North 4474, New Zealand.
Animals : an Open Access Journal From MDPI
|April 13, 2023
Summary
Equine Gastric Ulcer Syndrome (EGUS) now distinguishes between Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric Disease (EGGD). This review updates knowledge on both conditions, focusing on recent EGGD research.
Area of Science:
- Veterinary Medicine
- Equine Internal Medicine
- Gastroenterology
Background:
- Equine Gastric Ulcer Syndrome (EGUS) initially encompassed all equine gastric mucosal diseases.
- Two distinct entities, Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric Disease (EGGD), are now recognized under EGUS.
- A 2015 consensus highlighted knowledge gaps, particularly concerning EGGD.
Purpose of the Study:
- To provide an updated review of current knowledge on ESGD and EGGD.
- To synthesize recent research findings, especially regarding EGGD.
- To address evolved understanding since the last comprehensive review.
Main Methods:
- Literature review of recent studies on ESGD and EGGD.
- Analysis of research focusing on EGGD pathophysiology, diagnosis, and treatment.
- Synthesis of updated information on equine gastric mucosal diseases.
Main Results:
- Significant advancements in understanding EGGD pathophysiology, diagnosis, and treatment have occurred.
- Current knowledge on ESGD remains substantial, with ongoing research.
- The distinction between ESGD and EGGD is now well-established.
Conclusions:
- The understanding of equine gastric mucosal diseases has evolved significantly.
- EGGD is now a major focus of research, with substantial new findings.
- This review consolidates updated knowledge for equine internal medicine professionals.
Related Concept Videos
01:30Peptic Ulcer Disease I: Introduction
228
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
228
01:28Peptic Ulcer Disease II: Pathophysiology
604
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
604
01:26Peptic Ulcer Disease IV: Management
121
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
121
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
164
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
164
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
480
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
480
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
653
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
653